
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Bioasis
Deal Size : Undisclosed
Deal Type : Termination
Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Bioasis
Deal Size : Undisclosed
Deal Type : Termination

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
Details : Bioasis Technologies is developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous sys...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Biodexa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Merger

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Panobinostat lactate,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Midatech Pharma PLC Announces Headline Results of MTX110 Phase I DIPG Study
Details : The study has determined a proposed dose range for MTX110 for Phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering
Midatech Raises USD3 Million, Plans To Raise Further GBP1.8 Million
Details : The cash raised will be used to fund Midatech's MTX110 clinical programme, the development of an internal pipeline of Q-Sphera formulations for partnering, and for general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 18, 2020
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : H.C. Wainwright & Co
Deal Size : $3.0 million
Deal Type : Public Offering

Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Medulloblastoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2020

CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas
Details : MTX110 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 11, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Sabine Mueller, MD, PhD
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Panobinostat is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diffuse Intrinsic Pontine Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2018
Lead Product(s) : Panobinostat lactate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Sabine Mueller, MD, PhD
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Gelclair
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : PharPoint Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gelclair is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stomatitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2018
Lead Product(s) : Gelclair
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : PharPoint Research
Deal Size : Inapplicable
Deal Type : Inapplicable
